bioRxiv · 10.1101/2022.02.07.479493
In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
Abstract
In vitro selection of remdesivir-resistant SARS-CoV-2 revealed the emergence of a V166L substitution, located outside of the polymerase active site of the nsp12 protein, after 9 passages. V166L remained the only nsp12 substitution after 17 passages at a final concentration of 10 {micro}M RDV, conferring a 2.3-fold increase in EC50. When V166L was introduced into a recombinant SARS-CoV-2 virus, a 1.5-fold increase in EC50 was observed, indicating a high in vitro barrier to RDV resistance.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Checkmahomed, L., Du Pont, V., Riola, N. C., Perry, J., Li, J., Porter, D. P., Boivin, G.. 2022-02-12. In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.. https://doi.org/10.1101/2022.02.07.479493
Cite the original work for its findings. Save a collection to share your selection of sources.